FY2025 · ended Dec 31, 2025 · Revenue $1.36M, +66.1% YoY · Filed Mar 31, 2026
Cannapharmarx, Inc. (CPMD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.4 million and a net loss of $11.1 million. Free cash flow was -$794,621. As of Jun 30, 2026 it held $555 in cash and investments and $5.8 million in total debt.
Revenue (TTM)
$1.70M
Net income (TTM)
$-11.32M
Operating cash flow (TTM)
$-112,283
Free cash flow
$-794,621
+53.2% vs prior year
EPS
$-0.02
+0.0% vs prior year
Dividend per share
None
Shares outstanding
678.50M
+2.4% vs prior year
Net cash
$-5.78M
as of Jun 30, 2026
Operating margin
-170.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CPMD (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View County
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1081938
- Former names
- GOLDEN DRAGON HOLDING CO. (until Oct 27, 2014); CCVG, INC. (until Jan 12, 2011); CONCORD VENTURES, INC. (until Nov 17, 2010); CAVION TECHNOLOGIES INC (until Jul 25, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.4M | $820,137 | $0 | $0 | $0 |
| Operating income | -$3.3M | -$3.6M | -$5.2M | -$3.0M | -$14.5M |
| Net income | -$11.1M | -$9.9M | -$8.5M | -$8.8M | -$19.9M |
| Diluted EPS | -$0.02 | -$0.02 | $0.04 | — | — |
| Operating cash flow | -$789,102 | -$1.7M | -$1.4M | -$2.4M | -$563,573 |
| Free cash flow | -$794,621 | -$1.7M | — | — | — |
| Total assets | $7.0M | $10.8M | $5.4M | $114,330 | $8.7M |
| Total liabilities | $37.2M | $30.6M | $22.8M | $13.0M | $17.5M |
| Stockholders' equity | -$30.2M | -$19.8M | $17.3M | -$12.9M | -$8.8M |
| Cash and investments | $1,804 | $2,156 | $2,317 | $27,767 | $334,969 |
| Total debt | $6.0M | — | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 18, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 20, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Jan 13, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Other events
|
Dec 18, 2025 | Dec 12, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
All 365 Cannapharmarx, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.